vs

Side-by-side financial comparison of OR Royalties Inc. (OR) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

TREACE MEDICAL CONCEPTS, INC. is the larger business by last-quarter revenue ($62.5M vs $46.7M, roughly 1.3× OR Royalties Inc.).

OR Royalties Inc. is a Canadian company that holds royalties in gold, silver and diamond mines, principally in the form of net smelter returns and streams.Like its predecessor company, Osisko Mining, it is headquartered in Montreal, Quebec, with shares listed on the Toronto Stock Exchange and the New York Stock Exchange.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

OR vs TMCI — Head-to-Head

Bigger by revenue
TMCI
TMCI
1.3× larger
TMCI
$62.5M
$46.7M
OR

Income Statement — Q2 FY2022 vs Q4 FY2025

Metric
OR
OR
TMCI
TMCI
Revenue
$46.7M
$62.5M
Net Profit
$-9.4M
Gross Margin
80.6%
Operating Margin
-9.5%
Net Margin
-15.0%
Revenue YoY
-9.0%
Net Profit YoY
-1775.0%
EPS (diluted)
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OR
OR
TMCI
TMCI
Q4 25
$62.5M
Q3 25
$50.2M
Q2 25
$47.4M
Q1 25
$52.6M
Q4 24
$68.7M
Q3 24
$45.1M
Q2 24
$44.5M
Q1 24
$51.1M
Net Profit
OR
OR
TMCI
TMCI
Q4 25
$-9.4M
Q3 25
$-16.3M
Q2 25
$-17.4M
Q1 25
$-15.9M
Q4 24
$-501.0K
Q3 24
$-15.4M
Q2 24
$-21.2M
Q1 24
$-18.7M
Gross Margin
OR
OR
TMCI
TMCI
Q4 25
80.6%
Q3 25
79.1%
Q2 25
79.7%
Q1 25
79.7%
Q4 24
80.7%
Q3 24
80.1%
Q2 24
80.2%
Q1 24
80.2%
Operating Margin
OR
OR
TMCI
TMCI
Q4 25
-9.5%
Q3 25
-31.2%
Q2 25
-35.8%
Q1 25
-29.6%
Q4 24
-0.3%
Q3 24
-33.6%
Q2 24
-48.1%
Q1 24
-37.1%
Net Margin
OR
OR
TMCI
TMCI
Q4 25
-15.0%
Q3 25
-32.4%
Q2 25
-36.7%
Q1 25
-30.3%
Q4 24
-0.7%
Q3 24
-34.1%
Q2 24
-47.7%
Q1 24
-36.5%
EPS (diluted)
OR
OR
TMCI
TMCI
Q4 25
$-0.14
Q3 25
$-0.26
Q2 25
$-0.28
Q1 25
$-0.25
Q4 24
$-0.01
Q3 24
$-0.25
Q2 24
$-0.34
Q1 24
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OR
OR
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$48.4M
Total DebtLower is stronger
$222.8M
$55.6M
Stockholders' EquityBook value
$1.3B
$87.3M
Total Assets
$190.6M
Debt / EquityLower = less leverage
0.17×
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OR
OR
TMCI
TMCI
Q4 25
$48.4M
Q3 25
$57.4M
Q2 25
$69.3M
Q1 25
$76.1M
Q4 24
$75.7M
Q3 24
$82.8M
Q2 24
$95.0M
Q1 24
$110.0M
Total Debt
OR
OR
TMCI
TMCI
Q4 25
$55.6M
Q3 25
$53.5M
Q2 25
$53.5M
Q1 25
$53.4M
Q4 24
$53.3M
Q3 24
$53.2M
Q2 24
$53.2M
Q1 24
$53.1M
Stockholders' Equity
OR
OR
TMCI
TMCI
Q4 25
$87.3M
Q3 25
$89.2M
Q2 25
$97.6M
Q1 25
$105.3M
Q4 24
$112.9M
Q3 24
$104.9M
Q2 24
$112.1M
Q1 24
$126.4M
Total Assets
OR
OR
TMCI
TMCI
Q4 25
$190.6M
Q3 25
$196.6M
Q2 25
$206.4M
Q1 25
$205.8M
Q4 24
$217.1M
Q3 24
$212.9M
Q2 24
$226.1M
Q1 24
$242.7M
Debt / Equity
OR
OR
TMCI
TMCI
Q4 25
0.64×
Q3 25
0.60×
Q2 25
0.55×
Q1 25
0.51×
Q4 24
0.47×
Q3 24
0.51×
Q2 24
0.47×
Q1 24
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OR
OR
TMCI
TMCI
Operating Cash FlowLast quarter
$-8.0M
Free Cash FlowOCF − Capex
$-10.4M
FCF MarginFCF / Revenue
-16.7%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OR
OR
TMCI
TMCI
Q4 25
$-8.0M
Q3 25
$-9.1M
Q2 25
$-3.0M
Q1 25
$4.2M
Q4 24
$-4.2M
Q3 24
$-11.8M
Q2 24
$-13.9M
Q1 24
$-7.2M
Free Cash Flow
OR
OR
TMCI
TMCI
Q4 25
$-10.4M
Q3 25
$-11.9M
Q2 25
$-7.8M
Q1 25
$655.0K
Q4 24
$-7.3M
Q3 24
$-14.7M
Q2 24
$-15.6M
Q1 24
$-11.1M
FCF Margin
OR
OR
TMCI
TMCI
Q4 25
-16.7%
Q3 25
-23.7%
Q2 25
-16.5%
Q1 25
1.2%
Q4 24
-10.6%
Q3 24
-32.6%
Q2 24
-35.2%
Q1 24
-21.8%
Capex Intensity
OR
OR
TMCI
TMCI
Q4 25
3.8%
Q3 25
5.6%
Q2 25
10.1%
Q1 25
6.7%
Q4 24
4.5%
Q3 24
6.4%
Q2 24
3.9%
Q1 24
7.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons